Bochum

• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513282-39-00 5 2025-05-28 Hidradenitis Suppurativa (HS)
• CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS Ended recruitment
  2024-512720-11-00 5 2025-01-16 chronic venous ulcers (CVU)
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative … Ended recruitment
  2024-511796-15-00 5 2024-10-16 Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
• Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended recruitment
  2023-503383-17-01 5 2024-10-10 Female androgenetic alopecia
• A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment … Ended recruitment
  2024-515936-62-00 9 2024-10-10 Patients with advanced or metastatic gastrointestinal (GI) tumors.
• A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended recruitment
  2023-503692-24-00 5 2024-09-25 Cutaneous Lupus Erythematosus
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No … Ended recruitment
  2023-510279-80-00 4 2024-09-25 Prurigo nodularis
• Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended recruitment
  2023-507204-31-00 5 2024-07-26 Hidradenitis Suppurativa
• A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa Ended recruitment
  2023-505608-43-00 4 2024-07-04 Moderate to Severe Hidradenitis Suppurativa
• A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o … Ended recruitment
  2022-502518-98-00 5 2024-04-26 nonsegmental vitiligo
• Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended recruitment
  2023-503231-17-00 5 2024-04-26 Unresectable Pleural Mesothelioma
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co … Ended recruitment
  2022-502161-19-00 5 2024-03-12 Chronic Spontaneous Urticaria
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-dai … Ended recruitment
  2023-503531-18-00 6 2024-02-13 Prophylaxis of transplant rejection in adult kidney allograft recipien
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm … Ended recruitment
  2023-505122-34-00 5 2023-12-05 Plaque Psoriasis
• A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntingt … Ended recruitment
  2023-504628-24-00 4 2023-10-31 Huntington's Disease
• A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe … Ended recruitment
  2022-501644-15-01 4 2023-09-28 Mild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disea
• Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible f … Ended recruitment
  2024-515224-37-00 4 2023-08-29 Patients with MSI-high or MMR-deficient stage III colorectal cancer wh
• The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early … Ended recruitment
  2024-512980-29-00 4 2023-08-28 T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex … Ended recruitment
  2024-513462-19-00 5 2023-03-30 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol … Ended recruitment
  2024-513949-37-00 4 2023-03-16 previously untreated aggressive B-cell lymphoma

Showing 121–144 of 224 trials